Page last updated: 2024-08-05 11:01:54
nitrofuran antibiotic
A member of the class of furans in which the furan ring is substituted by a nitro group and which also has significant antibiotic properties.
ChEBI ID: 87230
Members (7)
Member | Definition | Role |
---|---|---|
furazolidone | A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. | furazolidone |
furylfuramide | A member of the class of acrylamides that is acrylamide which is substituted at positions 2 and 3 by 2-furyl and 5-nitro-2-furyl groups, respectively (the trans isomer). Formerly used as a food preservative, it was withdrawn from the market following suspicions of carcenogenicity. | (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide |
nifursol | nifursol | |
nifurtimox | Nifurtimox | |
nifurtoinol | An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group and at position 3 by a hydroxymethyl group. | nifurtoinol |
nitrofurantoin | An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. | nitrofurantoin |
nitrofurazone | A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections. | nitrofurazone |
Research
Studies (4,560)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 2,587 (56.73) | 18.7374 |
1990's | 434 (9.52) | 18.2507 |
2000's | 497 (10.90) | 29.6817 |
2010's | 688 (15.09) | 24.3611 |
2020's | 354 (7.76) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 327 (6.48%) | 5.53% |
Reviews | 339 (6.72%) | 6.00% |
Case Studies | 362 (7.18%) | 4.05% |
Observational | 11 (0.22%) | 0.25% |
Other | 4,004 (79.40%) | 84.16% |